Do antibacterial and antifungal combinations have better activity against clinically relevant fusarium species? in vitro synergism

Int J Antimicrob Agents. 2018 May;51(5):784-788. doi: 10.1016/j.ijantimicag.2017.10.017. Epub 2017 Nov 7.

Abstract

The aim of this study was to evaluate the susceptibility of 20 clinical isolates of Fusarium spp. to classic antifungals [amphotericin B (AmB), itraconazole (ITR), voriconazole (VRC) and caspofungin (CAS)] and to non-antifungal agents [amiodarone (AMD), doxycycline (DOX) and moxifloxacin (MFX)] by the broth microdilution method. Combinations between these antifungal and non-antifungal agents were also evaluated to determine the fractional inhibitory concentration indices using the chequerboard technique. Synergistic interactions were observed for the following combinations (% synergism): AMD + VRC, 80%; MFX + AmB, 75%; AMD + AmB, 65%; DOX + VRC, 60%; MFX + VRC, 55%; DOX + AmB, 50%; and AMD + CAS, 30%. Synergism was not observed for associations with ITR. Antagonism was not seen in any combination. These findings suggest that the combinations of AMD, DOX or MFX with AmB or VRC to have potential for future in vivo investigations.

Keywords: Amiodarone; Antifungal agents; Doxycycline; Fusarium spp; Moxifloxacin; Synergism.

MeSH terms

  • Amphotericin B / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Antifungal Agents / pharmacology*
  • Caspofungin
  • Drug Synergism
  • Drug Therapy, Combination
  • Echinocandins / pharmacology
  • Fusarium / drug effects*
  • Humans
  • Itraconazole / pharmacology
  • Lipopeptides / pharmacology
  • Microbial Sensitivity Tests
  • Voriconazole / pharmacology

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Itraconazole
  • Amphotericin B
  • Caspofungin
  • Voriconazole